Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.

Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.

Item

http://www.wikidata.org/entity/Q34002682

Q34002682

about

The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2)International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂ Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.Regulation of appetite to treat obesity.Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) receptor antagonist.High-resolution crystal structure of the human CB1 cannabinoid receptor.Rimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed mice Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonist.Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists.Crystal Structure of the Human Cannabinoid Receptor CB1.Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions.Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities.Diacylglycerol Lipase α Knockout Mice Demonstrate Metabolic and Behavioral Phenotypes Similar to Those of Cannabinoid Receptor 1 Knockout Mice.A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates.Targeting the endocannabinoid system: to enhance or reduce?Current pharmacotherapeutic concepts for the treatment of obesity in adults.Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists.Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.Cannabis sativa and the endogenous cannabinoid system: therapeutic potential for appetite regulation.Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists.The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives.In silico mapping of allosteric ligand binding sites in type-1 cannabinoid receptor.Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.Methylsulfonylpyrazolyl oxadiazoles and thiadiazoles as potent, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.Body temperature as a mouse pharmacodynamic response to bombesin receptor subtype-3 agonists and other potential obesity treatments.Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans.In vitro and in vivo metabolism of a novel cannabinoid-1 receptor inverse agonist, taranabant, in rats and monkeys.Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist.Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics.Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.A neutral CB1 receptor antagonist reduces weight gain in rat.

P2860

Q24656123-B90B4A1B-D729-4BBE-8786-4A7CFDEF0BFF Q28298445-A3F574F2-439A-4C3C-84D9-422F956D5AC4 Q30366778-D48AFC50-B178-49D7-BBF8-4E6073818B68 Q30403705-CFA08233-AA7C-4BFB-8406-2D9A274BCE76 Q33659650-8E83FE4B-337A-4CA0-9725-B42F958A80E0 Q33694212-BF8FED55-A013-4889-9F19-E791BF790339 Q33718134-9D265D0F-63F3-42BB-B848-1AFC3866C1D5 Q34293591-1F9C4B59-AA32-4538-AC28-0E593680E4C6 Q34453695-E8ACC6EF-F72A-49AC-A35E-B0AEB53CED24 Q34543208-E6CE5058-986B-4A30-A0FF-857FD28ED55E Q34992139-0502C405-2F9F-43E3-BAD5-80289B36A0A0 Q35228889-C7ED87A8-2A83-424D-9737-8026559C9BB1 Q35672654-6D9A7547-7DD7-481B-BB0F-4860309D3FD4 Q36368922-0FF124F5-9E82-45A0-85B9-694E2411D566 Q37150745-0D991252-A213-498A-8220-38DB8010D534 Q37368688-5E2C0696-AEDF-4AA8-8492-76C25D223A55 Q37387204-29C9B16C-08EA-4336-BEEC-3B40BB5FC135 Q37581457-BFB44973-CCBE-4053-B363-3ABEE18B368D Q37826693-1E2E6D03-385C-4EB3-86C9-26036166B3D7 Q37862977-76412B4D-6FD9-4A5C-B976-4A51230B1C98 Q37984087-D21FEB85-A9E3-4751-B538-C0938C0E348E Q38124458-328ADAAD-FF32-4DE4-B43A-7C40D175A72A Q38612135-EF30EB1A-DA8A-4044-B7F1-240B30058FBD Q38684679-7896CF96-825A-4513-8851-14A8B7189EF5 Q39959231-1B33280C-1F42-440D-9098-C830022E5607 Q42921046-FB0275A9-2598-4B71-B857-5BB56D0F13E9 Q42932797-E05CBCF7-FABA-4EFC-8953-8147485466BC Q42978612-2CB8D73F-4362-42B0-A26F-BFFCEF2A6370 Q43270612-01A1FA4A-45D8-41D0-8C26-FA5B44E5FEEA Q46308352-AB10D195-F81C-4B33-8934-A19003CDA5DE Q46570608-F40F4977-3787-48E2-A478-48ECA22ECAD5 Q46932962-7E9C1DF3-CC21-48E4-B483-F4646552D23C

P2860

Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.

Item

http://www.wikidata.org/entity/Q34002682

description

2007 nî lūn-bûn

@nan

2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu